Rational minded clear thinking people understand that goverment
agencies and medical research institutes are little more than
mouthpieces for industry put in place for purposes of legitamizing,
marketing, and self regulating.  I feel sorry for the fools and dupes
who think otherwise and place their trust in such corrupt hands as if
they are being looked out for by people who could not care less about
them.

About Karmeen Kulkarni of the American Diabetes Association:

http://www.powerpak.com/index.asp?page=courses/3102/disclaimer.htm&lsn_id=3102&s
how=lesson&type=disclaimer

Karmeen Kulkarni, MS, RD, BC-ADM
Coordinator, Diabetes Center
St. Mark's Hospital
Salt Lake City, Utah

Karmeen Kulkarni is a consultant for Eli Lilly and Co, and Lifescan,
Inc.

****
http://www.cecity.com/novo/basics/disclaim.htm

Karmeen Kulkarni, MS, RD, BC-ADM, CDE, has disclosed that she is a
consultant for Eli Lilly and Company and LifeScan Inc., a Johnson and
Johnson company.

***

She's written a dis-informational book on carb counting.

http://best-cooking-books.com/search_Karmeen_Kulkarni/searchBy_Author.html

*******

http://journal.diabetes.org/diabetesspectrum/00v13n4/page180.asp

"Karmeen Kulkarni, our nutrition expert, for taking us from the
old-school philosophy of looking at sugar as the forbidden fruit to
showing us how to incorporate sucrose into a healthy meal plan."

******

She has attacked low-carb diets before:

http://thunderbayfamilies.subportal.com/health/Womens/Pregnancy/Diet/107451.html

"In the long term, we don't know how [fad diets] are going to affect a
person's health," says Karmeen Kulkarni, a diabetes clinician at St.
Mark's Hospital in Salt Lake City. "When you cut out a whole set of
foods, you always are concerned about it."

Kulkarni reviewed the impact of fad diets on the blood sugar disease
at a symposium yesterday in New York City hosted by the American
Medical Association.

Some 58 million American adults are overweight, and the number of
people who are obese is up nearly 50 percent from the early 1990s,
Kulkarni says. Half of all Americans are on some kind of diet.

Diets such as the Atkins plan can lead to dramatic weight loss, at
least for a week or so, as the body sheds water that the now-missing
carbohydrates used to store.

But the majority of people who go on these rigid programs drop them
almost immediately, either because they crave fruit, vegetables, bread
and other sources of fiber, or because they don't like the side
effects, which can include bad breath.

Diabetics might notice near-term improvements in their blood sugar
levels when they start low-carb diets, Kulkarni says. But she says
those gains will fade when normal eating habits resume.

Foods low in fat often are doped with sugar and aren't necessarily
low-cal, Kulkarni says. They can also strain the body's metabolism,
she says, and promote not only weight gain but insulin resistance --
serious pitfall for established diabetics.

************

grants from eli lilly and Novartis:

http://www.aadenet.org/AnnualMeetings/AM04/programsessionWed.html
...
W16 In Hospital…In Control  
Virginia Valentine, MSN, CNS, APRN, BC-ADM, CDE
Diabetes Network, Inc
Albuquerque, NM

Karmeen Kulkarni, MS, RD, BC-ADM, CDE
St. Mark's Diabetes Center
Salt Lake City, UT
Anthony Furnary, MD, FACS, FACC
Starr-Wood Cardiac Group

Portland, OR

Recent research has demonstrated that intensified management of
glucose in hospitalized patients may improve outcomes in patients with
diabetes. To achieve the desirable near-normal glucose levels, a team
approach is essential to address the issues that complicate the
patient's outcomes. This presentation will explore research
implications for care of the acutely ill hospitalized patient and
apply current national guidelines to assist the participant with
development of a plan and tools needed to implement a diabetes
management program for hospitalized patients. (Level 2)

RPh: 069-999-04-016-L04 RN: ANCC 0304-058
RD: 5190, 5010, 5090

This program is supported by an educational grant from Eli Lilly &
Company.
...
W03 A Gut Reaction: Gut Hormones, the Incretin Effect, and
Implications for New Treatment Options
Steven Edelman, MD
Veteran Affairs Medical Center Dept of Endocrinology and Metabolism
San Diego, CA  Vivian Fonseca. MD, MRCP
Tulane Hospital Diabetes Education Program
New Orleans, LA  
Karmeen Kulkarni, MS, RD, BC-ADM, CDE
St. Mark's Diabetes Center
Salt Lake City, UT    
Recently, a hormone secreted by the GI tract (GLP-1) has been
identified as a factor in glucose homeostasis (incretin effect),
gastric emptying, regulation of appetite, and weight loss. The
development of GLP-1 mimetic and compounds that inhibit breakdown of
this hormone show promise for future therapeutic applications.
Discussion will include the dietician's perspective and practical
application of these concepts. (Level 2)

RPh: 069-356-04-010-L04 RN: ANCC 0304-047
RD: LNC: 5190, 5370, 5390

This program is supported by an education grant provided by Novartis
Pharmaceuticals Corporation.

*****

She is a member in good standing of the Diabetes Care and Education
Dietetic Practice Group

http://www.dce.org/about/annual2002to2003.pdf

second last page has the corporate sponsors of this group

********

She's involved with:

http://www.s2mw.com/heartofdiabetes/healthcare.html

The American Heart Association's The Heart Of DiabetesSM:
Understanding Insulin Resistance is brought to you through an
educational grant from Takeda Pharmaceuticals North America, Inc. and
Eli Lilly and Company.

********

a bit more about corporate sponsors of the AADE, American Association
of Diabetes Educators:

http://aade.online-daily.com/preview.htm

In just a few short months, Chris has already achieved several
important gains for AADE. Chief among them is furthering of funding to
launch the National Diabetes Education Outcomes System (NDEOS) into
the next phase. As most of you know, this is will provide the diabetes
care and education team with a complete reporting system to gather,
track and aggregate outcome measures unique to diabetes education and
self-management training. Additionally, NDEOS will also serve as a
data repository to support the integration of diabetes education into
clinical care.

Key to making this major project a reality is securing funding from 10
sponsors. We now have six – LifeScan, Inc., BD Consumer Healthcare,
Eli Lilly & Company, Roche Diagnostics, Novo Nordisk, and Bayer
HealthCare. As we have traveled around the country representing AADE
and NDEOS in these sponsorship meetings, I have been very impressed
with how well Chris has represented our organization.

search this page for "Corporate Symposia", yikes

*************

TC

More on Karmeen Kulkarni:

She was on the International Advisory Board and had a hand in writing
the Canadian Diabetes Association 2003 Clinical Practice Guidelines
for the Prevention and Management of Diabetes in Canada

Financial assistance for the Canadian Diabetes Association 2003
Clinical Practice Guidelines for the Prevention and Management of
Diabetes in Canada is generously provided by the following sponsors,
in the form of unrestricted
educational grants.

Primary Sponsors
Abbott Laboratories, Ltd.
Aventis Pharma Inc.
Bayer Diagnostics Inc.
Eli Lilly Canada Inc.
GlaxoSmithKline Inc.
Hoffmann-La Roche Ltd.
LifeScan Canada Ltd.
Merck Frosst/Schering Pharmaceuticals
Novo Nordisk Canada Inc.
Secondary Sponsors
Merck Frosst Canada Ltd.
Novartis Pharmaceuticals Canada Inc.
***

TC

Karmeen Kulkarni of the American Diabetes Association is a consultant
to Lifescan, a Johnson and Johnson company, guess what they market:

http://www.lifescan.com/

http://www.lifescan.com/professionals/apdc/program

So much for her integrity as a medical professional.

TC